treatment-resistant depression
Coverage of treatment-resistant depression in the Nexus archive.
- Eli Lilly makes $3.8 billion bet on psychedelic drugs
Eli Lilly will acquire a psychedelic drug developer for up to $3.8 billion, focusing on AtaiBeckley’s BPL-003 nasal spray in late-stage trials for treatment-resistant depression. Analysts project annual sales of $1-$2 billion if the drug succeeds. The company aims to leverage psychedelic chemicals for psychiatric treatments, though challenges in placebo-controlled trials and past industry scandals remain.
- Single infusion of controversial drug changed severe depression symptoms within hours, study finds
A study reviewed 26 clinical trials involving over 1,100 patients, finding that a single ketamine infusion significantly reduced severe depression symptoms within four hours and lowered suicidal thoughts within 24 hours. The analysis suggests ketamine may offer rapid relief for treatment-resistant depression, though it carries risks like dissociation and nausea.
- FDA moves to fast-track review of 3 psychedelic drug studies
The FDA granted fast-track review to three companies studying psychedelic therapies for depression and PTSD, with two focusing on psilocybin for treatment-resistant depression and major depressive disorder. This move aligns with the Trump administration's push for potential approval of psychedelic treatments.